Co-Diagnostics, Inc. Common Stock (CODX)vsStryker Corporation (SYK)
CODX
Co-Diagnostics, Inc. Common Stock
$1.53
-6.13%
HEALTHCARE · Cap: $5.94M
SYK
Stryker Corporation
$315.13
0.00%
HEALTHCARE · Cap: $120.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 4034664% more annual revenue ($25.12B vs $622,490). SYK leads profitability with a 12.9% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 65/100 (C+).
CODX
Hold41
out of 100
Grade: D
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CODX.
Margin of Safety
-19.7%
Fair Value
$263.22
Current Price
$315.13
$51.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 76.7% year-over-year
Earnings expanding 30.8% YoY
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -125.9% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CODX
The strongest argument for CODX centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 76.7% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : CODX
The primary concerns for CODX are Market Cap, Profit Margin, Return on Equity.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CODX profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.
CODX carries more volatility with a beta of 1.43 — expect wider price swings.
CODX is growing revenue faster at 76.7% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Bottom Line
SYK scores higher overall (65/100 vs 41/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Co-Diagnostics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?